The PharmaTimes Sales Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
13th November 2018
The PharmaTimes Communications of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
13th November 2018
The PharmaTimes Marketer of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this special 25th anniversary ceremony that celebrates the very best the industry has to offer.
13th November 2018
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
13th November 2018
Oxford BioDynamics, Italian research institute pair to develop biomarkers for autism spectrum disorder (ASD).
13th November 2018
Evox Therapeutics has secured £655,000 in funding from Duchenne UK, to support exploration of its exosome-based therapeutic platform for the condition.
13th November 2018
Swedish Orphan Biovitrum AB has entered into an agreement to buy US rights to AstraZeneca’s Synagis, licensed for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV).
13th November 2018
Public Health England is urging the public to ensure they have had two doses of MMR vaccine after outbreaks of measles are confirmed across England.
13th November 2018
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
12th November 2018
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
12th November 2018
US regulators have accepted an application from AstraZeneca and MSD for use of Lynparza as maintenance treatment for patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer.
12th November 2018
The UK House of Commons' Health and Social Care Committee has requested documents and evidence from Vertex Pharmaceuticals, NHS England and the National Institute for Health and Care Excellence (NICE) regarding ongoing and lengthy negotiations about NHS funding for the firm’s cystic fibrosis treatments.
12th November 2018
The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca/MSD's Lynparza to a wider patient population with ovarian cancer.
9th November 2018
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
9th November 2018
Liverpool University is to coordinate a European research project that aims to develop new devices and methods for diagnosing and treating kidney disease.
9th November 2018
